The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).
 
Florent Amatore
No Relationships to Disclose
 
Shaum Sridharan
No Relationships to Disclose
 
Arivarasan Karunamurthy
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Ravi Patel
No Relationships to Disclose
 
Melissa Pugliano-Mauro
No Relationships to Disclose
 
Seungwon Kim
No Relationships to Disclose
 
Mohammad Haroon Asif Choudry
No Relationships to Disclose
 
James F. Pingpank
No Relationships to Disclose
 
Matthew Peter Holtzman
No Relationships to Disclose
 
Uma Maheswari Duvvuri
No Relationships to Disclose
 
Robert L. Ferris
Stock and Other Ownership Interests - Novasenta
Consulting or Advisory Role - Adagene; Adaptimmune; Aduro Biotech; Bicara Therapeutics; Bristol-Myers Squibb; Cantenion; Coherus Biosciences; CureVac; CytoAgents; Eisai Europe; EMD Serono; Eterna Therapeutics; Everest Clinical Research; F. Hoffmann LaRoche; Federation Bio; Genmab; Genocea Biosciences; Hookipa Pharma; Instil Bio; Kowa Research Institute; Lifescience Dynamics; Macrogenics; MeiraGTx; Merck; Merus NV; Mirati Therapeutics; Mirati Therapeutics; Mirror Biologics; Nanobiotix; Novartis; Novasenta; Numab; OncoCyte; Pfizer; PPD; Rakuten Medical; Regeneron; Sanofi; Seagen; SIRPant Immunotherapeutics; VIR Biotechnology; Zymeworks; Zymeworks
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Novasenta; Tesaro
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
John M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Ankyra Therapeutics; Applied Clinical Intelligence; AXIO Research; Becker Pharmaceutical Consulting; Bristol Myers Squibb; Cancer Network; Cancer Study Group; Checkmate Pharmaceuticals; CytomX Therapeutics; DermTech; Fenix Group International; Harbour BioMed; Immunocore; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Lytix Biopharma; Magnolia Innovation; Merck; Natera; Novartis; OncoCyte; OncoSec; PATHAI; Pfizer; Piper Sandler; PyrOjas Corporation; Regeneron; Replimune; Scopus BioPharma; SR One Capital Management; Takeda; Valar Labs
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron
 
Yana G. Najjar
Consulting or Advisory Role - Bristol Myers Squibb; Immunocore; InterVenn Biosciences; Mallinckrodt/Therakos; Merck; Pfizer
Speakers' Bureau - Immunocore; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer/EMD Serono (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Istari
 
Filippo Pullara
Employment - PredxBio
Stock and Other Ownership Interests - PredxBio, Inc.
Expert Testimony - PredxBio, Inc.
 
Chakra Chennubhotla
Employment - PredxBio, Inc.
Leadership - PredxBio, Inc.
Stock and Other Ownership Interests - PredxBio, Inc.
Patents, Royalties, Other Intellectual Property - PredxBio, Inc.
 
Hassane M. Zarour
Honoraria - maat pharma
Consulting or Advisory Role - Checkmate Pharmaceuticals
Research Funding - Merck Sharp & Dohme (Inst); Tesaro (Inst)
 
Diwakar Davar
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy